Webinar - Time to ‘Think Kawasaki Disease’

In this webinar, Professor Robert Tulloh and Professor Paul Brogan will provide a comprehensive update on this important condition. They will highlight how out-dated information about Kawasaki Disease is hampering best practice for affected children. They will present the recent research findings (UK and Ireland) on incidence – including revealing data on lifetime heart damage caused for far too many children.
Date: -
Time: -
Spaces available

Free of charge

About this webinar

With Kawasaki Disease on the rise in the UK and across the globe, it is now the commonest cause of acquired heart disease in children worldwide. 

The webinar will provide essential information about diagnosis considerations and how to overcome the challenges presented by more common ‘similars’. 

By the end of this webinar, delegates will be able to:

  • Understand the diagnosis considerations for Kawasaki Disease – including differences of presentation across ages, and when to THINK Kawasaki Disease
  • Develop knowledge of differential diagnosis considerations and red flags for Kawasaki Disease
  • Develop knowledge of the urgency with which the disease needs to be treated – confidence to consider Kawasaki Disease 
  • Gain awareness of disease severity and the criticality of EARLY treatment
  • Abandon prevailing ‘myths’ around this disease which are hampering treatment / adversely impacting children affected

Top benefits for participants

  • Kawasaki Disease is increasingly common - EXPECT to see it, be READY to treat it
  • Be ready to THINK Kawasaki Disease when you see 5 days of fever
  • Consider Kawasaki Disease in the very young (infants) as this is when it can be most serious
  • Acknowledge that delay = increasing risk of heart damage! Kawasaki Disease is a medical emergency


The target audience for this webinar:

  • Paediatric trainees
  • General paediatricians
  • Paediatricians with an interest in cardiology
  • Paediatric cardiologists
  • Paediatric rheumatologists
  • Paediatric infectious diseases specialists
  • GPs

It is also suitable for an international audience, with caveats on data (which is UK & Ireland) and treatment approaches which will be most relevant to the UK context.


Professor Robert Tulloh is a Consultant Paediatric Cardiologist at University Hospitals Bristol and the Bristol Heart Institute. He is Professor in Congenital Cardiology and Pulmonary Hypertension at the University of Bristol, Clinical Lead for Department of Paediatric Cardiology and Training Programme Director. He graduated in Medicine from Oxford University, obtained CCST in Paediatrics, and CCST in Paediatric Cardiology. His training locations included Dartmouth Medical School, Johns Hopkins Hospital and as a British Heart Foundation Research Fellow at the Institute of Child Health, London on neonatal pulmonary hypertension.  He is involved actively in research and has been a member of the Kawasaki research community for many years, both in the UK and as part of the International Kawasaki Disease Research Group. He is a key author in major trials in Pulmonary Hypertension and on RSV prophylaxis in congenital heart disease. He has been Director of Medical Education and has written 44 book chapters, has more than 241 published items and has given over 220 presentations at international meetings. 

Paul Brogan is Professor of vasculitis and honorary Paediatric rheumatologist at UCL/Great Ormond Street Hospital NHS Foundation Trust. He is section head for infection inflammation and rheumatology at UCL Institute of child health; and specialty lead for paediatric rheumatology at Great Ormond Street Hospital. He has developed a programme of research into rare inflammatory diseases of the young. He has published over 150 scientific papers; edited and co-authored four textbooks; and has written several international textbook chapters. He has a long standing interest in Kawasaki disease, previously exploring late cardiovascular sequelae, and is currently chief investigator of the proposed Kawasaki disease coronary artery aneurysm prevention trial (KD-CAAP).